SERVICES
Three services. One path from science to investment.
We work with research institutions in the life sciences — biotech, health, and pharma — at three points on the same path: deciding whether to move an asset, shaping how to move it, and preparing the people who will carry it. Take one service or all three. Each begins with a free scoping call and a fixed timeline, agreed before any fee is committed.
01 — Decision Integrity Review
Due diligence
The question you’re facing: Should we move this forward?
Before you spend more on an asset, you get one integrated read on whether it holds — assessed across science, regulation, intellectual property, manufacturing, market, and financing, the same lens an investor or acquirer will use. We also test how artificial intelligence changes the picture: whether it strengthens the asset, or quietly erodes its value. The findings come together in a single view your board can act on. Where the answer is “not yet,” you learn what would have to change.
You receive: a board-ready decision dossier. How it runs: three stages — scoping and document review, integrated analysis, then the written report. Behind it: we have led due diligence for pharmaceutical licensing and acquisitions, and run more than sixty-five investment reviews across four venture funds. Timeline: 3–6 weeks.
02 — Integrated Venture Strategy
Strategy for spin-out and licensing
The question you’re facing: How should we move it forward?
Once the decision is made, you need a route to value and the evidence to fund it. We turn a promising result into a strategy you can take to investors — the plan, the bottom-up financial model, and the case a spin-out or a licensing partner will need. Spin out or licence, now or in stages: we set out the options and back the recommendation with numbers. Where AI is part of the story, we pressure-test it in the model, so the plan reflects what the technology can actually carry. We work alongside your team and your process, not around it.
You receive: a strategic roadmap ready to put in front of investors. How it runs: three phases — strategic diagnostic, venture strategy with financial modelling, then the funding package. Behind it: we have structured several spin-outs out of corporate research and built ventures from the earliest stage. Timeline: 4–8 weeks.
03 — Founder & Investor Readiness
Coaching and mentoring
The question you’re facing: Can the people leading this project win investors and deliver?
A strong asset still needs people who can lead it and present it well. We work directly with the researchers and founders carrying a project — sharpening how they position it, how they think about capital, and how they handle a board or an investor meeting. And we stay with them past the first decision.
You receive: leadership that stands up in front of investors, and a development plan to match. How it runs: tailored sessions — assessment, investor positioning and capital strategy, then a development plan. Behind it: we have coached medical and scientific teams inside a global pharmaceutical group, and supported founders long after the investment was made. Timeline: 1–3 months.
How we work
Rolling intake, so you can start when you’re ready. Delivered remotely or on site, in English or French. Senior operators do the work throughout — no junior team on your project.
What we don’t do: We do not write EU grant proposals, manage EU-funded projects, or take success fees on funding applications. Formal legal, regulatory, and audit opinions stay with licensed professionals. We give you the judgement to decide — the binding paperwork stays where it belongs.
Not sure which service fits?
Start with the scoping call, and we’ll point you to the right one.
Start a conversation